Zymeworks Announces Participation in Upcoming Investor Conferences

Rhea-AI Summary

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company, will participate in the H.C. Wainwright Global Investment Conference from May 24-26. They will hold virtual one-on-one meetings and a corporate presentation on May 24 at 7 a.m. ET. This presentation will be accessible via Zymeworks’ website. Zymeworks focuses on developing next-generation multifunctional biotherapeutics, with lead candidate zanidatamab currently in multiple trials for solid tumors expressing HER2. For more details, visit their corporate site.

VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference:

• H.C. Wainwright Global Investment Conference. Zymeworks will participate virtually in one-on-one meetings on May 24^th – 26^th and a corporate presentation will be available virtually on May 24^th at 7 a.m. ET.

The presentation will be available on Zymeworks’ website at http://ir.zymeworks.com/events-and-presentations.

About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks’ second clinical candidate, ZW49, is a novel bispecific HER2‑targeted antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with global biopharmaceutical companies. For more information on our ongoing clinical trials visit www.zymeworksclinicaltrials.com. For additional information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220502005052/en/

Investor Inquiries:

Jack Spinks

(604) 678-1388

ir@zymeworks.com

Media Inquiries:

Diana Papove

(604) 678-1388

media@zymeworks.com

Source: Zymeworks Inc.

FAQ

When will Zymeworks participate in the H.C. Wainwright Global Investment Conference?

Zymeworks will participate in the H.C. Wainwright Global Investment Conference from May 24 to 26.

What is the timing for Zymeworks' corporate presentation during the conference?

Zymeworks' corporate presentation will be available virtually on May 24 at 7 a.m. ET.

Where can I watch Zymeworks' presentation?

The presentation will be available on Zymeworks' website.

What is Zymeworks' lead clinical candidate?

Zymeworks' lead clinical candidate is zanidatamab, which targets HER2.

What is the stock symbol for Zymeworks?

The stock symbol for Zymeworks is ZYME.